Axim Biotechnologies, Inc. (OTCPK: AXIM) is an innovative biotechnology company dedicated to the research, development, and commercialization of proprietary diagnostic tools. The company's primary mission is to address unmet medical needs by developing novel, accurate, and rapid diagnostic solutions, with a significant focus on ophthalmology, particularly Dry Eye Disease (DED). Axim aims to improve patient outcomes through early and precise disease detection and management, leveraging its expertise in biomarker analysis and assay development.
The San Diego headquarters serves as the company's main operational center, overseeing corporate strategy, research and development programs, clinical trial management, business development, and administrative functions.
Located in the Sorrento Valley biotech cluster, the headquarters benefits from proximity to leading research institutions, a skilled talent pool, and a vibrant ecosystem of innovative companies. The facility likely comprises modern office space and potentially specialized laboratory areas for R&D activities.
Axim Biotechnologies likely fosters a dynamic and innovative work environment, characterized by scientific rigor, collaboration, and a strong focus on achieving breakthroughs in medical diagnostics. The culture would emphasize agility and a patient-centric approach, typical of biotech firms driving new healthcare solutions.
The headquarters' location in San Diego is strategically vital, providing Axim access to world-class research facilities, potential partnerships, and investment opportunities crucial for a company in the competitive biotech sector.
While Axim Biotechnologies is headquartered in the USA, its diagnostic products and research initiatives have global relevance. The company's global presence is primarily manifested through its pursuit of international patents, engagement in clinical trials that may span multiple countries to ensure diverse population data and meet various regulatory standards, and strategic planning for future commercialization of its diagnostic tools in key markets worldwide. Its collaborations may also extend to international research institutions and partners.
10655 Sorrento Valley Rd, Suite 200
San Diego
CA
USA
Address: N/A
The company focuses on leveraging the rich biotech ecosystem of San Diego for its primary functions. Any international activities are typically project-specific rather than managed through dedicated regional offices.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AXIM' leadership includes:
AXIM has been backed by several prominent investors over the years, including:
Over the past year, Axim Biotechnologies has focused on strengthening its scientific and clinical leadership team with key appointments, including a new Chief Medical Officer. There have been no publicly announced C-suite executive departures during this period.
Discover the tools AXIM uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Axim Biotechnologies likely utilizes standard corporate email address formats. A common pattern involves combining the employee's first initial and last name, followed by the company's domain.
[first_initial][last]@aximbiotech.com (e.g., jsmith@aximbiotech.com)
Format
jhuemoeller@aximbiotech.com
Example
75%
Success rate
GlobeNewswire • March 26, 2024
Axim Biotechnologies announced the filing of two new provisional patent applications for its innovative rapid diagnostic assay. This assay is designed to quantify levels of MMP-9, a key inflammatory biomarker for Dry Eye Disease, aiming to improve the diagnosis and management of the condition....more
GlobeNewswire • March 20, 2024
Axim Biotechnologies strengthened its scientific advisory board with the appointments of Dr. Hories Fung and Dr. Thomas Stoss. Their expertise in ophthalmology and diagnostic development will support the company's ongoing research programs and product development pipeline....more
GlobeNewswire • November 29, 2023
Axim Biotechnologies announced the appointment of Dr. Joost J. Oppenheim as its new Chief Medical Officer. Dr. Oppenheim will be responsible for leading the company's clinical development strategies, medical affairs, and providing oversight for clinical trials....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AXIM, are just a search away.